Kolon Life Science Inc
KOSDAQ:102940
Kolon Life Science Inc
Cost of Revenue
Kolon Life Science Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
K
|
Kolon Life Science Inc
KOSDAQ:102940
|
Cost of Revenue
-₩112.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-2%
|
Yuhan Corp
KRX:000100
|
Cost of Revenue
-₩1.3T
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Cost of Revenue
-₩34.1B
|
CAGR 3-Years
-158%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Cost of Revenue
-₩661.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Cost of Revenue
-₩98.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-7%
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Cost of Revenue
-₩280B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-32%
|
See Also
What is Kolon Life Science Inc's Cost of Revenue?
Cost of Revenue
-112.2B
KRW
Based on the financial report for Dec 31, 2023, Kolon Life Science Inc's Cost of Revenue amounts to -112.2B KRW.
What is Kolon Life Science Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-2%
Over the last year, the Cost of Revenue growth was 10%. The average annual Cost of Revenue growth rates for Kolon Life Science Inc have been -1% over the past three years , 2% over the past five years , and -2% over the past ten years .